IC
DMRA

Ikarian Capital’s Damora Therapeutics DMRA Stock Holding History

Ikarian Capital’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.73M Hold
335,710
– – 0.94% 30
2026
Q1 		$8.69M Buy
335,710
+50,000
+18% +$1.29M 0.71% 39
2025
Q4 		$6.57M Buy
+285,710
New +$4.97M 0.51% 54

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Ikarian Capital's DMRA Position: Q2 2026 in Review

Ikarian Capital held its Damora Therapeutics (DMRA) position steady in Q2 2026 at 335,710 shares worth $8.73M. The position accounts for 0.94% of the portfolio, ranked #30.

Ikarian Capital first reported a position in DMRA in Q4 2025 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Ikarian Capital held 335,710 shares of Damora Therapeutics worth $8.73M as of Q2 2026.
  • Ikarian Capital left its Damora Therapeutics share count unchanged in Q2 2026.
  • Damora Therapeutics made up 0.94% of Ikarian Capital's portfolio in Q2 2026, its #30 holding.
  • Ikarian Capital first reported a position in Damora Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.